Efficiency of Use of Baracetinib in Treatment of Lupus Nephritis
Status:
Active, not recruiting
Trial end date:
2023-04-01
Target enrollment:
Participant gender:
Summary
Patients with systemic lupus erythematosus have substantial unmet medical need. Baricitinib
is an oral selective Janus kinase (JAK)1 and JAK2 inhibitor that we hypothesised might have
therapeutic benefit in patients with systemic lupus erythematosus and had a diagnosis of
systemic lupus erythematosus, and had active renal disease as defined by Systemic Lupus
Erythematosus Disease Activity Index-2000 (SLEDAI-2K). Efficacy and safety analyses included
all patients who received at least one dose of study drug.